O18-3 Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC

Kentaro Yamazaki,Hisateru Yasui,Akiyoshi Kanazawa,Kaname Yamashita,Naohiro Okano,Masahiro Goto,Hiromichi Ebi,Akihito Tsuji,Yu Sunakawa,Nobuhisa Matsuhashi,Yukiko Abe,Satoshi Yuki,Hiroya Taniguchi,Takayuki Yoshino,Hideaki Bando,Manabu Shiozawa,Hironaga Satake,Yuki Horita ,Shosaku Nomura ,Nobutaka Takahashi

doi:10.1016/j.annonc.2022.05.056

O18-3 Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC

Kentaro Yamazaki, Hisateru Yasui + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.05.056

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jul 1, 2022
License type: publisher-specific-oa

Affiliation: Shizuoka Cancer Center

#2nd-line Chemotherapy #Predictor Of Efficacy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Plasma angiogenesis factors are known to be a prognostic factor for metastatic colorectal cancer (mCRC), but its significance as a predictor of efficacy in 2nd-line (2L) chemotherapy (chemo) combined with angiogenesis inhibitors has not been established.

Full Text